| ||
| ||
| ||
| Excess Bleeding Forces Halt to Apixaban ACS Trial MedPage Today By Peggy Peck, Executive Editor, MedPage Today Apixaban, a novel anticoagulant that seemed to be on a glide path to FDA approval, has been detoured by excess bleeding that caused a data safety monitoring board to halt a phase III trial of the drug, ... See all stories on this topic » | ||
| Hong Kong: Bird Flu Checks Increase New York Times By KEVIN DREW Health authorities said Thursday that they were increasing their checks on poultry coming from mainland China and at farms and markets across the region after government officials confirmed the first case of bird flu in seven years in the ... See all stories on this topic » | ||
| Amgen's Bone Drug Denosumab Cleared to Treat Fractures in Cancer Patients Bloomberg By Rob Waters - Fri Nov 19 05:01:00 GMT 2010 Amgen Inc.'s osteoporosis drug denosumab was approved by US regulators for reducing fractures in prostate and breast cancer patients, an indication that could boost sales to $2.4 billion in five years. ... See all stories on this topic » | ||
| Nearly 1 in 5 Americans had mental illness in 2009 msnbc.com By Julie Steenhuysen CHICAGO, Nov 18 (Reuters Life!) - More than 45 million Americans, or 20 percent of US adults, had some form of mental illness last year, and 11 million had a serious illness, US government researchers reported on Thursday. ... See all stories on this topic » | ||
| Study finds dying cancer patients often don't use hospices Seattle Times By LEE BOWMAN Hospice care was designed for cancer patients. Medicare has covered the end-of-life services for nearly 30 years. Yet a new study finds that only about half of Medicare patients dying from cancer are getting any hospice services in their ... See all stories on this topic » |
Tip: Use a minus sign (-) in front of terms in your query that you want to exclude. Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment